Overview

Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia

Status:
Active, not recruiting

Trial end date:
2025-08-01

Target enrollment:

Participant gender:

Summary

A clinical study to evaluate a treatment with two drugs, named Ofatumumab and Ibrutinib, in patients with lymphoblastic acute leukemia who have been already treated with other therapies.

Phase:

Phase 2

Details

Lead Sponsor:

Gruppo Italiano Malattie EMatologiche dell'Adulto

Treatments:

Antibodies, Monoclonal
Ofatumumab